Along this line, a recent preprint documents heightened cell death susceptibility of PLK4-overexpressing ovarian cancer cells toward carboplatin treatment and improved overall survival and therapy responsiveness of patients showing centrosome amplification (60). This evidence concerns the gene PLK4 and ovarian carcinoma.